When does the patent for Glecaprevir/Pibrentasvir expire?

Introduction to Glecaprevir/Pibrentasvir
 
Glecaprevir/Pibrentasvir is a once-daily, pangenotypic, fixed-dose combination regimen that has emerged as a highly effective therapeutic option for the treatment of chronic hepatitis C virus (HCV) infection. Glecaprevir functions as a nonstructural protein 3/4A (NS3/4A) protease inhibitor, whereas Pibrentasvir acts as a nonstructural protein 5A (NS5A) inhibitor. Together they work synergistically to inhibit viral replication across HCV genotypes 1–6. This combination regimen has been studied in multiple Phase II and III clinical trials, demonstrating high sustained virologic response rates (SVR12) even in patients with compensated liver disease and in populations with comorbidities such as chronic kidney disease or coinfection with HIV. The combination is marketed under the tradenames MAVYRET® in the United States and MAVIRET® in other regions, making it a clinically important asset in the management of HCV, particularly given its short duration of treatment (often 8 or 12 weeks) and its ability to address a broad range of the patient population.

Indications and Usage 
This regimen is indicated for the treatment of adults with chronic HCV infection, with clinical studies and real-world evidence supporting its use in patients both with and without cirrhosis. It is appropriate for a wide range of HCV genotypes and has been evaluated in special populations such as pediatric patients (three to 12 years old) as well as in post-transplant patients. Its excellent safety and efficacy profile, with high SVR rates and minimal drug-related serious adverse events, render it a frontline treatment in HCV management. The broad therapeutic application is reflected in clinical trial data, which underscore its versatility in addressing different subgroups of patients with chronic HCV, including those who are treatment naive as well as those who have experienced previous treatment failures.

Patent Information

Patent Details and Expiration Date 
When discussing the patent information for a pharmaceutical product such as Glecaprevir/Pibrentasvir, two key aspects are often considered: the specific patent claims covering the active pharmaceutical ingredients (and/or specific formulations) and the period of market exclusivity that these patents confer. In the case of Glecaprevir/Pibrentasvir, the available references from our trusted Synapse source do not provide a direct, explicit numerical expiration date for the patent covering this combination. For example, one website reference titled “Mavyret patent expiration” notes that “only the drug patent owner can launch products that use this active ingredient until these patents expire.” However, the text does not contain a specific year or date at which the patent protection lapses.

Patent protection for major pharmaceutical assets such as Glecaprevir/Pibrentasvir typically runs for up to 20 years from the filing date under national laws, with additional extensions possible in certain jurisdictions to compensate for delays during the clinical development and regulatory review processes. In the United States, for instance, regulatory exclusivity and patent term extensions might extend the effective market exclusivity beyond the nominal 20-year period if the drug undergoes significant delays before marketing approval. Although several references provided stress that the patent remains a barrier until its expiration, no reference among those provided explicitly states the exact expiration date for the Glecaprevir/Pibrentasvir patents.

It is also possible that proprietary filings covering distinct aspects of the drug—such as its chemical entities, formulation, or use—may have different expiration dates. Complex patent portfolios for combination regimens may involve multiple patents with staggered expiration dates. For a regimen as significant as Glecaprevir/Pibrentasvir, manufacturers are likely to have employed strategies to extend protection via secondary patents related to dosing, formulation, or specific indications. Despite substantial documentation and discussion around patent life cycles in the pharmaceutical sector, the precise expiration date for Glecaprevir/Pibrentasvir is not directly provided in the references at hand.

Thus, while we are informed that the patent protection remains enforceable until such time as the patent(s) expire—precluding generic entry—there is no definitive expiration date provided in the available references. Stakeholders and market analysts are advised to monitor announcements from the holder (for example, through regulatory filings or updates on corporate websites) for updated information regarding the expiration timeline.

Patent Laws and Regulations 
The regulatory framework governing pharmaceutical patents is complex and involves both national and international legal regimes. Patent protection on drugs typically rests on the application of national patent laws as well as international treaties such as the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Under these frameworks, patents generally offer 20 years of protection from the filing date. In some jurisdictions, especially in cases where there is significant delay in obtaining marketing approval from regulatory agencies (such as the FDA in the United States), manufacturers may be eligible for patent term extensions or Supplementary Protection Certificates (SPCs).

For combination drugs like Glecaprevir/Pibrentasvir, the patent portfolio may be rich and multifaceted. This means that even if one patent expires, complementary patents (for example, those covering manufacturing processes, formulations, or methods of use) might still provide barrier protection against generic competitors. These regulatory provisions underscore the importance of strategic patent management in the pharmaceutical industry. As emphasized in various sources, obtaining and enforcing pharmaceutical patents demands an understanding of both domestic and international patent practices, making the delineation of an exact expiry date a challenging task without access to the complete portfolio details maintained by the patent owner.

Market Implications

Impact on Drug Pricing 
The expiration of patents plays a pivotal role in drug pricing dynamics. Historically, when patents expire for drugs with high-priced brand exclusivity, the market subsequently experiences intense price competition leading to significant reductions in price. Systematic literature reviews have shown that drug prices tend to decrease by anywhere from 6.6% to 66% within one to five years after patent expiry, depending on various market factors and country-specific policies.

For a drug regimen like Glecaprevir/Pibrentasvir, the continuation of patent protection means that until the relevant patents expire, the drug retains its market exclusivity, allowing the manufacturer to set pricing without generic competition. Once the patent protection lapses, generic manufacturers can enter the market, which typically drives down prices. Although the precise patent expiration date for Glecaprevir/Pibrentasvir is not explicitly given in our references, the market expectation is that once the expiration occurs, there might be a significant reduction in price similar to what has been observed in other blockbuster drugs. This reduction in price post-patent expiry will be important for healthcare systems aiming to reduce expenditure on costly branded treatments, while simultaneously increasing patient access.

Generic Drug Entry 
Generic drug entry is one of the most important market dynamics that follow patent expiration. As long as the drug is covered by valid patents, generic manufacturers are legally barred from marketing generic formulations that use the same active ingredients, formulation, or method of use. The reference indicates that “only the drug patent owner can launch products that use this active ingredient until these patents expire,” signaling that generic entry remains blocked.

When generic competition enters the market following patent expiry, empirical studies have shown that generic drug market shares can rapidly reach high percentages—sometimes between 56% to 92% of the overall market—while brand names experience significant market share erosion. Economic models and empirical analyses suggest that increased generic competition leads not only to lower prices but also to enhanced market access for patients. The typical pattern seen in other treatment areas has been a swift decline in branded drug prices once generics are launched, with profit margins on the originator brand becoming squeezed by aggressive pricing by generic competitors.

In summary, generic drug entry following patent expiry tends to create a more competitive environment, which can be beneficial for both payers and patients but may also decrease the revenue for the originator company—a factor that such companies try to forestall by employing strategies such as patent term extensions. For Glecaprevir/Pibrentasvir, this means that while the current market remains relatively insulated as long as the patents are in force, any expiration event will likely open the door to new market entrants and result in significant pricing pressure.

Future Considerations

Competition and Market Dynamics 
Looking ahead, the expiration of patents for widely used drugs can have profound implications on market dynamics. As generics gain entry, competition increases and the market share for the original drug declines, which is well documented in pharmacoeconomic studies. With a drug like Glecaprevir/Pibrentasvir that has been highly effective in the treatment of HCV, the prospect of generic competition could lead to a dramatic reduction in price—potentially benefiting payers and patients. However, the originator company may also face strategic challenges in maintaining market share.

The interplay between patent protection, regulatory exclusivity, and market dynamics is constantly evolving. Competitive intelligence such as patent expiration dates, pricing trends, and regulatory changes are essential for forecasting future market behavior. Based on research in the field, companies attempt to maximize their period of exclusivity through strategies like patent extensions and secondary patents covering optimized formulations or expanded indications. Although the data in our provided references do not offer a definitive expiration date for Glecaprevir/Pibrentasvir, the competitive landscape suggests that when the patents do eventually expire, the competitive pressure from generic entrants will be substantial.

Moreover, studies indicate that there exists a range of policy instruments that governments use to manage the post-patent market phase. In some European countries, regulatory measures such as the Reference Price System force a steep price decline once generics enter the market. In contrast, countries with less aggressive generic promotion might experience a more gradual decline in prices. Consequently, the economic impact of any eventual patent expiration on Glecaprevir/Pibrentasvir will not only depend on the expiration date but also on the regulatory environment of each market.

Potential for New Treatments 
The eventual expiration of the patent for Glecaprevir/Pibrentasvir may also stimulate further innovation in the field of antiviral treatment. The expiration of a key patent typically triggers both competitive generic entry and renewed investment in research and development for novel treatment approaches. With the entrance of generic versions, patients may benefit from a lower cost of therapy, while the originator company may focus on next-generation formulations or entirely new therapeutic targets in HCV and related diseases.

In addition, the cycle of patent expiration and subsequent generic entry is known to act as an impetus for further research. Pharmaceutical companies, already well aware of the limited duration of market exclusivity, frequently invest in strategies to broaden the indications of a drug, develop improved formulations, or create combination regimens that can secure new patents. This phenomenon is widely discussed in scholarly articles and industry analyses. Thus, while Glecaprevir/Pibrentasvir currently represents a key treatment option with a patent-protected market, its expiration in the future may be accompanied by an accelerated pace of innovation, both from the original manufacturer and new market players.

Furthermore, as newer direct-acting antivirals or complementary therapies are developed, the landscape for HCV treatment can evolve, resulting in a situation where even if the patent for Glecaprevir/Pibrentasvir expires, the competitive intensity is buffered by the availability of novel treatments. This scenario creates a dynamic ecosystem, ensuring that patients have access to a range of therapeutic options while fostering a competitive environment that can drive down costs.

Conclusion 
In summary, the current evidence from Synapse and affiliated sources outlines the strategic importance of the patent system in protecting pharmaceutical innovations such as Glecaprevir/Pibrentasvir. Although multiple sources emphasize that generic entry is legally barred until the relevant patents expire, none of the provided references offer a specific expiration date for Glecaprevir/Pibrentasvir. It is well understood that patents in the pharmaceutical arena generally offer a protection period of up to 20 years from the filing date—with the possibility of extensions in jurisdictions such as the United States—to compensate for regulatory delays. For a combination regimen as clinically robust and commercially significant as Glecaprevir/Pibrentasvir, the patent portfolio may be complex and consist of several patents with potentially staggered expiration dates.

From a market perspective, the preservation of patent protection supports higher pricing and exclusivity, whereas patent expiry is typically followed by significant price reductions, rapid generic entry, and increased competition. This competitive shift has important implications for healthcare budgets, while also encouraging further innovation. With the eventual expiration of the patent—whenever that specific date is officially disclosed—the market dynamics will shift toward increased generic penetration and more competitive pricing, potentially driving down treatment costs for HCV.

Future considerations include the role of patent extension strategies and the emergence of next-generation treatments. The strategic management of intellectual property has profound effects not only on pricing and market share but also on the innovation trajectory within the pharmaceutical industry. As pharmaceutical companies adapt to these challenges, it is likely that new formulations, expanded indications, and innovative treatment combinations will emerge, maintaining the overall progress in HCV management.

Detailed Conclusion: 
While the exact expiration date for the patent covering Glecaprevir/Pibrentasvir is not explicitly stated in any of the Synapse sources provided, the available information clarifies that the drug’s market exclusivity is maintained by valid patents that continue to block generic entry. Patent regimes typically grant up to 20 years of protection from the filing date—with potential extensions to compensate for regulatory delays—which means that the proprietary status of Glecaprevir/Pibrentasvir is safeguarded for a considerable period. The lack of a precise expiration date in the provided references indicates that additional detailed patent portfolio information may be available through regulatory filings or official patent databases from the patent holder.

From both clinical and market viewpoints, the expiration of these patents is a critical juncture that will likely lead to substantial declines in drug pricing and robust generic competition, while simultaneously spurring further innovation in the field. Stakeholders should therefore remain vigilant regarding updates from the patent owner and related intellectual property repositories to obtain definitive information on the expiration timeline. Ultimately, this dynamic interplay between patent protection, market exclusivity, and subsequent generic entry shapes the future landscape of HCV treatment and reflects broader trends in pharmaceutical innovation and market competition.

In light of the available evidence, the precise answer to "When does the patent for Glecaprevir/Pibrentasvir expire?" remains undetermined from these references. Continued monitoring of official patent filings and regulatory updates is essential to obtain the exact expiration date and to better understand the consequent market implications.

Discover Eureka LS: AI Agents Built for Biopharma Efficiency

Stop wasting time on biopharma busywork. Meet Eureka LS - your AI agent squad for drug discovery.

▶ See how 50+ research teams saved 300+ hours/month

From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.